Results 181 to 190 of about 4,554,738 (310)

Improved nucleic acid sensing, exemplified using pure target DNA sequences, by MO capture probes compared to DNA capture probes, as revealed from PO₂ ^-, PO₃ ^- and nucleobase mass peaks. [PDF]

RSC Adv
Bhattacharya B, Kundu J, Ghosal A, Paul A, Qasim M, Dattasarma S, Mana T, Dutta SS, Sinha S, Dey S, Dasgupta S, Mukhopadhyay R.   +11 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Department of Health and Human Services Recombinant DNA Advisory Committee National Institutes of Health - Minutes of Meeting - September 12, 1997

, 1998
Recombinant DNA Advisory Committee
core  

DNA Restriction

The discovery of enzymes that could cut and paste DNA made genetic engineering possible. Restriction enzymes, found naturally in bacteria, can be used to cut DNA fragment at specific sequences, while another enzyme, DNA ligase, can attach or rejoin DNA ...

core   +1 more source

Genomic Stress and DNA Repair During Macrophage Differentiation and Inflammatory Activation. [PDF]

Int J Mol Sci
Jo SG, Jeon J, Jeon YJ, Park SJ, Kang TH.   +4 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee minutes of meeting June 12- 13, 1997

, 1998
Recombinant DNA Advisory Committee
core  

Integrated Biomarker Assessment of Bifenthrin, Chlorpyrifos and Endosulfan Toxicity in Indigenous Carps (Catla catla and Labeo rohita): Oxidative Stress, Genotoxicity and Nuclear Alterations. [PDF]

Vet Med Sci
Naz H, Abdullah S, Ahmed T, Abbas K, Ijaz MU, Ullah Q, Naz S, Khan RU, Rossi L, Ahmad S, Alonaizan R.   +10 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source